A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorFudan University
About this trial
This is an open-label, single-arm, prospective, multicenter clinical study designed to evaluate the efficacy and safety of envafolimab in combination with lenvatinib for the treatment of patients with clear cell renal cell carcinoma (ccRCC) accompanied by liver metastases. The Department of Urology at Fudan University Shanghai Cancer Center serves as the primary research center.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Envafolimab+Lenvatinib
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Fudan University
Lead sponsor
Huadong Hospital
Collaborator
Source ClinicalTrials.gov